Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cook first to file paclitaxel-eluting stent:

This article was originally published in Clinica

Executive Summary

Cook has become the first company to submit a marketing application for a paclitaxel-eluting coronary stent anywhere in the world, after filing the device for European CE mark approval. The filing was based on the results of Cook's European-based ELUTES clinical trial, which revealed a binary restenosis rate of just 3.1% due to paclitaxel's cytostatic mechanism of action in inhibiting neointimal hyperplasia. "Cook could begin selling its first drug-eluting coronary stents in Europe during the second quarter of this year," predicted Kem Hawkins, the Bloomington, Indiana firm's president.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel